论文部分内容阅读
抗血管生成治疗是肿瘤常见的治疗方式之一。贝伐单抗作为抗血管内皮生长因子的单克隆抗体,是目前唯一被批准用于晚期非小细胞肺癌(NSCLC)一线治疗的抗血管生成制剂。为了扩大贝伐单抗用于晚期NSCLC的适应证,大量研究继续探索贝伐单抗在一线治疗的联合形式外,还致力于探索其在后线及跨线治疗的疗效和安全性。《中国肿瘤临床》2017年第3期“国家基金研究进展综述”栏目,来自四川大学华西临床医学院
Anti-angiogenic therapy is one of the common treatments for cancer. Bevacizumab, the monoclonal antibody against vascular endothelial growth factor, is currently the only antiangiogenic agent approved for first-line treatment in advanced non-small cell lung cancer (NSCLC). In order to expand the use of bevacizumab in patients with advanced NSCLC, a large number of studies continue to explore the combination of first-line treatment of bevacizumab and to explore the efficacy and safety of bevacizumab in both posterior and cross-line therapy. “Chinese Oncology” 2017 the third period “Review of National Fund Research” column, from Sichuan University West China School of Medicine